Rapid and Cost-effective Spectrophotometric Method for Rivastigmine Transdermal Patch Quantification
Article Sidebar
Main Article Content
Abstract
Introduction: Several formulations of rivastigmine have been approved for Alzheimer’s disease including transdermal patch which increase in compliance and decrease in adverse drug reactions. However, there have been limited reports on direct quantification. Objectives: The aim of this study was to design a simple, rapid, and cost-effective spectrophotometric method for direct quantification of rivastigmine in transdermal formulation. The results were also evaluated for linearity, precision, accuracy, and repeatability. Methods: Rivastigmine was extracted by sonicating in water. The different concentrations of rivastigmine in the patch were investigated for linearity and analyzed for correlation coefficient (r2). The precision was determined by using intra-day, inter-day, and repeatability techniques. The accuracy was investigated by using spike and unspike techniques. Results: The UV spectrum showed the maximum absorption at 260 nm. The linearity was obtained in this study with r2 greater than 0.99. The percentages of relative standard deviation from the precision assay were 1.0-3.5%, 0.4-2.5%, and less than 1% for intra-day, inter-day, and repeatability assays, respectively. The percentages of recovery were obtained with the range of 90-110%. The total duration of this method was less than 2 hours. Conclusion: This procedure would be a useful, uncomplicated, rapid and quality-control analytical method for direct quantification of rivastigmine quantity in transdermal patch formulation. This method would be clinically useful for pharmacokinetic study such as drug absorption through skin.
Article Details
References
2. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. Int J Clin Pract. 2009;63:799-805.
3. Emre M, Bernabei R, Blesa R, Bullock R, Cunha L, Daniëls H, et al. Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther. 2010;16:246-53.
4. Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia. Expert Opin Drug Saf. 2010;9:167-76.
5. Kurz A, Farlow M, Lefevre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. Int J Clin Pract. 2009;63:799-805.
6. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane, R. A six-month doubleblind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease - Rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry. 2007;22:456-67.
7. Darreh-Short T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia. Expert Opin Drug Saf. 2010;9:167-76.
8. Simon A, Amaro MI, Healy AM, Cabral LM, de Sousa VP. Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation. Int J Pharm. 2016;512:234-41.
9. Kale MN. Development of validated RP-HPLC method for quantitative estimation of rivastigmine hydrogen tartrate in transdermal drug delivery system. J Pharm Sci Res. 2014;5:1892-902.
10. Sharmila SK, Srilakshimi M, Renukadevi G, Rahaman SA, Shanthakumari K. Development and validation of UV-spectrophotometric method for the estimation of rivastigmine tartrate in bulk and pharmaceutical dosage form. Indo American Journal of Pharmaceutical Research. 2013;3:8394-9.
11. Pedroso TM, Salgado RRN. Validation of analytical methodology for quantification of cefazolin sodium pharmaceutical dosage form by high performance liquid chromatography to be applied for quality control in pharmaceutical industry. Braz J Pharm Sci. 2014;50:213-23.
12. Chavan RR, Bhinge SD, Bhutkar MA, Randive DS. Development and validation of spectrophotometric methods for simultaneous estimation of furosemide and spironolactone by Vierordt’s method in bulk and combined tablet dosage form. ACTA CHEMICA IASI 2018:26:74-90.
13. Hasin F, Mukhlasy H, Hussain I, Hossain M, Hasan M. Validation of spectrophotometric dissolution method for modified release trimetazidine pharmaceutical dosage form. J Innov Pharm Biol Sci. 2017;4:68-73.
14. Desai VN, Afieroho OE, Dagunduro BO, Okonkwo TJ, Ndu CC. A simple UV spectrophotometric method for the determination of leveofloxacin in dosage formulation. Trop J Pharm Res. 2011;10:75-9.